Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationMen's HealthInsulinIssue 730

AACE: Testosterone Improves Insulin Sensitivity

Testosterone supplementation has an insulin sensitizing effect in patients with diabetes.... 

Advertisement

Manav Batra, MD, of the University of Buffalo, said during a presentation, that "according to research, testosterone also increases in expression of mediators of signaling and reductions in factors that interfere." "Our data for the first time shows men with type 2 diabetes and hypogonadotropic hypogonadism are more insulin resistant as compared to men who have normal testosterone." "This hypogonadotropic hypogonadism is associated with lower expression of mediators of insulin signaling in adipose tissue as compared to men who have normal testosterone. Following the testosterone replacement in these men, the expression of mediators of insulin signaling increases, and there is a reduction in expression of mediators interfering with insulin signaling that improves insulin sensitivity."

In a randomized trial, Batra and colleagues recruited 91 men with hypogonadotropic hypogonadism (HH, n=41) and type 2 diabetes to evaluate the effect of testosterone replacement on insulin resistance.

Patients with HH were assigned testosterone (250 mg) or placebo (1 ml saline) injected intramuscularly every 2 weeks for 6 months. The researchers collected fasting blood samples, and performed fat biopsies and hyperinsulinemic euglycemic clamps, at baseline and at 6 months.

Results from the clamps showed that patients with HH have 28% lower glucose infusion rates (GIR) for a given rate of insulin infusion vs. eugonadal patients; a 30% increase in GIR was observed with testosterone treatment, consistent with a reversal of insulin resistance.

In HH adipose tissue compared to eugonadal, basal expression of mediators of insulin signaling -- including insulin resistance (IR), insulin receptor substrate (IRS-1) and glucose transporter (GLUT-4) -- was lower by 32%, 35% and 27% (P<0.05), respectively.

Following testosterone, the adipose tissue expression of IR, IRS-1 and GLUT-4 increased significantly by 63±15%, 54±17% and 59±14%, respectively, and a decrease was observed in the expression of protein-tyrosine phosphatase by 23±8% and toll-like receptor 4 by 21±11%, which interfere with insulin signaling.

Reductions were seen in several others areas that interfere with signaling, including mononuclear cells expression of suppressor of cytokine signaling-3 by 27±8% and plasma concentrations of free fatty acids and C-reactive protein by 35% and 26%, (P<0.05) respectively.

Practice Pearls:
  • Testosterone supplementation can improve insulin sensitivity in patients with diabetes.
  • Note that these studies were published as abstracts and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Batra M. Abstract 303. Presented at: AACE 23rd Annual Scientific & Clinical Congress; May 13-18, 2014; Las Vegas, Nevada. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  MedicationMen's HealthInsulinIssue 730

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you be interested in a urine test strip product that measures microalbumin and creatinine levels to determine kidney failure risk in your patients?

CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75